Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 181

Related Citations for PubMed (Select 22456540)

1.

Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.

Nguyen HL, Ruxrungtham K, Delaugerre C.

Intervirology. 2012;55(4):287-95. doi: 10.1159/000336658. Epub 2012 Mar 23.

PMID:
22456540
2.

Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.

Maïga AI, Malet I, Soulie C, Derache A, Koita V, Amellal B, Tchertanov L, Delelis O, Morand-Joubert L, Mouscadet JF, Murphy R, Cissé M, Katlama C, Calvez V, Marcelin AG.

Antivir Ther. 2009;14(1):123-9.

PMID:
19320246
3.

Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes.

Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, Tomberlin GH, Carter HL 3rd, Broderick T, Sigethy S, Seki T, Kobayashi M, Underwood MR.

Antimicrob Agents Chemother. 2011 Oct;55(10):4552-9. doi: 10.1128/AAC.00157-11. Epub 2011 Aug 1.

4.

Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.

Brenner BG, Lowe M, Moisi D, Hardy I, Gagnon S, Charest H, Baril JG, Wainberg MA, Roger M.

J Med Virol. 2011 May;83(5):751-9. doi: 10.1002/jmv.22047. Epub 2011 Feb 25.

PMID:
21360548
5.

Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.

Hassounah SA, Mesplède T, Quashie PK, Oliveira M, Sandstrom PA, Wainberg MA.

J Virol. 2014 Sep 1;88(17):9683-92. doi: 10.1128/JVI.00947-14. Epub 2014 Jun 11.

6.
7.

Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.

Saladini F, Meini G, Bianco C, Monno L, Punzi G, Pecorari M, Borghi V, Di Pietro M, Filice G, Gismondo MR, Micheli V, Penco G, Carli T, De Luca A, Zazzi M; ARCA Collaborative Group.

Clin Microbiol Infect. 2012 Oct;18(10):E428-30. doi: 10.1111/j.1469-0691.2012.03917.x. Epub 2012 Jun 21.

8.

In vitro analysis of the susceptibility of HIV-1 subtype A and CRF01_AE integrases to raltegravir.

Bellecave P, Malato L, Calmels C, Reigadas S, Parissi V, Andreola ML, Fleury H.

Int J Antimicrob Agents. 2014 Aug;44(2):168-72. doi: 10.1016/j.ijantimicag.2014.04.013. Epub 2014 Jun 2.

PMID:
24935032
9.

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.

Malet I, Fourati S, Charpentier C, Morand-Joubert L, Armenia D, Wirden M, Sayon S, Van Houtte M, Ceccherini-Silberstein F, Brun-Vézinet F, Perno CF, Descamps D, Capt A, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2011 Dec;66(12):2827-30. doi: 10.1093/jac/dkr389. Epub 2011 Sep 19.

10.

Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.

Garrido C, Soriano V, Geretti AM, Zahonero N, Garcia S, Booth C, Gutierrez F, Viciana I, de Mendoza C.

Antiviral Res. 2011 Jun;90(3):164-7. doi: 10.1016/j.antiviral.2011.03.178. Epub 2011 Mar 23.

PMID:
21439330
11.
12.

The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes.

Sierra S, Lübke N, Walter H, Schülter E, Reuter S, Fätkenheuer G, Bickel M, da Silva H, Kaiser R, Esser S; SnoB-Study group.

Med Microbiol Immunol. 2011 Nov;200(4):225-32. doi: 10.1007/s00430-011-0194-1. Epub 2011 Apr 8.

PMID:
21475993
13.

Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection.

Garrido C, Geretti AM, Zahonero N, Booth C, Strang A, Soriano V, De Mendoza C.

J Antimicrob Chemother. 2010 Feb;65(2):320-6. doi: 10.1093/jac/dkp423. Epub 2009 Dec 9.

14.

Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.

Gutiérrez C, Hernández-Novoa B, Pérez-Elías MJ, Moreno AM, Holguín A, Dronda F, Casado JL, Moreno S.

HIV Clin Trials. 2013 Jan-Feb;14(1):10-6. doi: 10.1410/hct1401-10.

PMID:
23372110
15.

Emerging patterns and implications of HIV-1 integrase inhibitor resistance.

Geretti AM, Armenia D, Ceccherini-Silberstein F.

Curr Opin Infect Dis. 2012 Dec;25(6):677-86. doi: 10.1097/QCO.0b013e32835a1de7. Review.

PMID:
23086187
16.

In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.

Canducci F, Ceresola ER, Saita D, Castagna A, Gianotti N, Underwood M, Burioni R, Lazzarin A, Clementi M.

J Antimicrob Chemother. 2013 Nov;68(11):2525-32. doi: 10.1093/jac/dkt220. Epub 2013 Jun 24.

17.

Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.

Malet I, Wirden M, Fourati S, Armenia D, Masquelier B, Fabeni L, Sayon S, Katlama C, Perno CF, Calvez V, Marcelin AG, Ceccherini-Silberstein F.

J Antimicrob Chemother. 2011 Jul;66(7):1481-3. doi: 10.1093/jac/dkr152. Epub 2011 Apr 7.

18.

Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.

Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, Niedziela-Majka A, Barnes TL, Novikov N, Chen X, Svarovskaia ES, McColl DJ, White KL, Miller MD.

Antimicrob Agents Chemother. 2013 Jun;57(6):2654-63. doi: 10.1128/AAC.02568-12. Epub 2013 Mar 25.

19.

Natural polymorphisms of HIV-1 subtype-C integrase coding region in a large group of ARV-naïve infected individuals.

Dimonte S, Babakir-Mina M, Aquaro S, Perno CF.

Infection. 2013 Dec;41(6):1097-102. doi: 10.1007/s15010-013-0464-5. Epub 2013 Apr 26.

PMID:
23620062
20.

Natural polymorphisms of HIV-1 CRF01_AE integrase coding region in ARV-naïve individuals in Cambodia, Thailand and Vietnam: an ANRS AC12 working group study.

Nouhin J, Donchai T, Hoang KT, Ken S, Kamkorn J, Tran T, Ayouba A, Peeters M, Chaix ML, Lien TX, Nerrienet E, Ngo-Giang-Huong N.

Infect Genet Evol. 2011 Jan;11(1):38-43. doi: 10.1016/j.meegid.2010.10.014. Epub 2010 Nov 19.

PMID:
21094281
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk